Study: NCT03129555

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dabigatran Etexilate Oral Capsule
Description: After cluster randomization, the cluster will use dabigatran to all their patients with venous thromboembolism when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time. It is the clusters and not the patient that are randomized.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dabigatran Etexilate Oral Capsule
Description: After cluster randomization, the cluster will use dabigatran to all their patients with venous thromboembolism when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time. It is the clusters and not the patient that are randomized.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dabigatran Etexilate Oral Capsule
Description: After cluster randomization, the cluster will use dabigatran to all their patients with venous thromboembolism when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time. It is the clusters and not the patient that are randomized.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dabigatran Etexilate Oral Capsule
Description: After cluster randomization, the cluster will use dabigatran to all their patients with venous thromboembolism when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time. It is the clusters and not the patient that are randomized.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rivaroxaban Oral Tablet
Description: After cluster randomization, the cluster will use rivaroxaban to all their patients with venous thromboembolism when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time. It is the clusters and not the patient that are randomized.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rivaroxaban Oral Tablet
Description: After cluster randomization, the cluster will use rivaroxaban to all their patients with venous thromboembolism when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time. It is the clusters and not the patient that are randomized.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rivaroxaban Oral Tablet
Description: After cluster randomization, the cluster will use rivaroxaban to all their patients with venous thromboembolism when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time. It is the clusters and not the patient that are randomized.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rivaroxaban Oral Tablet
Description: After cluster randomization, the cluster will use rivaroxaban to all their patients with venous thromboembolism when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time. It is the clusters and not the patient that are randomized.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Edoxaban Oral Tablet
Description: After cluster randomization, the cluster will use edoxaban to all their patients with venous thromboembolism when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time. It is the clusters and not the patient that are randomized.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Edoxaban Oral Tablet
Description: After cluster randomization, the cluster will use edoxaban to all their patients with venous thromboembolism when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time. It is the clusters and not the patient that are randomized.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Edoxaban Oral Tablet
Description: After cluster randomization, the cluster will use edoxaban to all their patients with venous thromboembolism when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time. It is the clusters and not the patient that are randomized.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Edoxaban Oral Tablet
Description: After cluster randomization, the cluster will use edoxaban to all their patients with venous thromboembolism when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time. It is the clusters and not the patient that are randomized.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apixaban Oral Tablet
Description: After cluster randomization, the cluster will use apixaban to all their patients with venous thromboembolism when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time. It is the clusters and not the patient that are randomized.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apixaban Oral Tablet
Description: After cluster randomization, the cluster will use apixaban to all their patients with venous thromboembolism when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time. It is the clusters and not the patient that are randomized.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apixaban Oral Tablet
Description: After cluster randomization, the cluster will use apixaban to all their patients with venous thromboembolism when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time. It is the clusters and not the patient that are randomized.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apixaban Oral Tablet
Description: After cluster randomization, the cluster will use apixaban to all their patients with venous thromboembolism when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time. It is the clusters and not the patient that are randomized.